Tanezumab for treating moderate to severe chronic pain caused by osteoarthritis [ID1603]
In development [GID-TA10711] Expected publication date: 15 September 2021
Search results
563 results
-
-
Melanoma: assessment and management
In development [GID-NG10155] Expected publication date: 06 July 2022
-
Omalizumab for treating chronic rhinosinusitis with nasal polyps [ID1650]
In development [GID-TA10558] Expected publication date: TBC
-
Crizanlizumab for preventing sickle cell crises in sickle cell disease [ID1406]
In development [GID-TA10470] Expected publication date: TBC
-
Belimumab for the treatment of active autoantibody-positive systemic lupus erythematosus (Review of TA397) [ID1591]
In development [GID-TA10626] Expected publication date: 21 July 2021
-
Sodium thiosulfate for preventing hearing loss in people with cancer who are under 18 and having cisplatin chemotherapy [ID1001]
In development [GID-TA10611] Expected publication date: TBC
-
Bulevirtide for treating chronic hepatitis D [ID3732]
In development [GID-TA10652] Expected publication date: 20 October 2021
-
Weight Management
In development [GID-NG10182] Expected publication date: 22 June 2023
-
Adults with complex needs: social work interventions including assessment, care management and support
In development [GID-NG10145] Expected publication date: 27 April 2022
-
Integrated sensor-augmented pump therapy systems for managing blood glucose levels in type 1 diabetes (update of DG21) (provisional title)
In development [GID-DG10042] Expected publication date: 13 April 2022
-
Erenumab for preventing migraine [ID1188]
In development [GID-TA10302] Expected publication date: TBC
-
Anakinra for treating active Stills disease [ID1463]
In development [GID-TA10392] Expected publication date: TBC
-
Stroke rehabilitation in adults
In development [GID-NG10175] Expected publication date: 14 December 2022
-
Chronic kidney disease: assessment and management (update)
In development [GID-NG10118] Expected publication date: 20 July 2021
-
Asthma: diagnosis, monitoring and chronic asthma management
In development [GID-NG10186] Expected publication date: TBC
-
Nivolumab for treating squamous cell carcinoma of the head and neck after platinum-based chemotherapy (CDF Review TA490) [ID1585]
In development [GID-TA10538] Expected publication date: TBC
-
Tobacco: preventing uptake, promoting quitting and treating dependence (update)
In development [GID-NG10086] Expected publication date: 01 September 2021
-
Caesarean section (update)
In development [GID-NG10081] Expected publication date: 31 March 2021
-
Ectopic pregnancy and miscarriage: diagnosis and initial management (update)
In development [GID-NG10173] Expected publication date: TBC
-
Zanubrutinib for treating Waldenström's macroglobulinaemia [ID1427]
In development [GID-TA10705] Expected publication date: 17 November 2021
-
Hypertension in adults: diagnosis and management (update)
In development [GID-NG10177] Expected publication date: 19 April 2023
-
Pembrolizumab with pemetrexed and platinum-based chemotherapy for previously treated EGFR-positive metastatic non-small-cell lung cancer [ID3873]
In development [GID-TA10766] Expected publication date: TBC
-
Melphalan flufenamide with dexamethasone for treating relapsed or refractory multiple myeloma [ID3862]
In development [GID-TA10744] Expected publication date: TBC
-
Nivolumab for treating resected high-risk invasive urothelial cancer [ID2694]
In development [GID-TA10742] Expected publication date: 05 January 2022
-
Abiraterone for treating newly diagnosed high risk metastatic hormone-naive prostate cancer [ID945]
In development [GID-TA10122] Expected publication date: TBC
-
Cemiplimab for untreated PD-L1-postive advanced or metastatic non-small-cell lung cancer [ID3839]
In development [GID-TA10725] Expected publication date: TBC
-
Constipation (opioid induced) - lubiprostone [ID646]
In development [GID-TAG367] Expected publication date: 01 October 2014
-
Pembrolizumab in combination for untreated, locally recurrent inoperable or metastatic, triple negative breast cancer [ID1546]
In development [GID-TA10417] Expected publication date: 15 September 2021
-
Ofatumumab for treating relapsing multiple sclerosis [ID1677]
In development [GID-TA10557] Expected publication date: TBC
-
Olaparib for previously treated, hormone-relapsed metastatic prostate cancer with homologous recombination repair gene mutations [ID1640]
In development [GID-TA10584] Expected publication date: 05 May 2021
-
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies [ID2697]
In development [GID-TA10582] Expected publication date: 19 May 2021
-
Olaparib with bevacizumab for maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer [ID1652]
In development [GID-TA10526] Expected publication date: TBC
-
Daratumumab in combination for untreated multiple myeloma when stem cell transplant is suitable [ID1510]
In development [GID-TA10449] Expected publication date: TBC
-
Betibeglogene autotemcel for treating transfusion-dependent beta-thalassaemia [ID968]
In development [GID-TA10334] Expected publication date: TBC
-
Antenatal care
In development [GID-NG10096] Expected publication date: 11 August 2021
-
Esketamine for treatment-resistant depression (ID1414)
In development [GID-TA10371] Expected publication date: TBC
-
Self harm: assessment, management and preventing recurrence
In development [GID-NG10148] Expected publication date: 18 May 2022
-
Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy [ID2727]
In development [GID-TA10674] Expected publication date: TBC
-
Cabozantinib for previously treated advanced hepatocellular carcinoma [ID3917]
In development [GID-TA10805] Expected publication date: 23 March 2022
-
Nivolumab for untreated advanced hepatocellular carcinoma [ID1248]
In development [GID-TA10221] Expected publication date: TBC
-
Mexiletine for treating myotonia in adults with non-dystrophic myotonic disorders ID1488
In development [GID-TA10432] Expected publication date: TBC
-
SACT
In development [GID-NG10184] Expected publication date: TBC
-
Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease (CDF Review of TA558) [ID1681]
In development [GID-TA10644] Expected publication date: 17 March 2021
-
Rivogenlecleucel for treating haematological cancers in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1601]
In development [GID-TA10467] Expected publication date: TBC
-
Pembrolizumab with platinum-based chemotherapy for untreated advanced oesophageal cancer [ID3741]
In development [GID-TA10613] Expected publication date: 13 October 2021
-
Advocacy services for adults with health and social care needs
In development [GID-NG10156] Expected publication date: TBC
-
Looked-after children and young people
In development [GID-NG10121] Expected publication date: 27 September 2021
-
Tebentafusp for treating metastatic or unresectable HLA-A*02:01 positive uveal melanoma [ID1441]
In development [GID-TA10428] Expected publication date: 20 July 2022
-
Nivolumab with temozolomide and radiotherapy for newly diagnosed glioblastoma with MGMT methylation [ID1582]
In development [GID-TA10495] Expected publication date: 18 August 2021
-
PredictSURE IBD and IBDX to guide treatment of Crohn's disease
In development [GID-DG10029] Expected publication date: TBC